Abstract：
Biomarkers play a key role in patients with testicular germ cell tumors in a variety of clinical contexts, including initial diagnosis, prognostication, monitoring treatment response, and posttreatment surveillance. Although the classic serum tumor markers for testicular germ cell tumors are essential for clinical management, the low sensitivity (particularly for seminoma and teratoma) and potential for false positives has spurred novel biomarker discovery and validation efforts. Here, we review the current state of serum-based biomarkers for testicular germ cell tumors, with a focus on the classic serum tumor markers and emerging class of microRNA markers.
摘要：
在各种临床背景下，生物标志物在睾丸生殖细胞肿瘤患者中发挥关键作用。包括初步诊断,预测,监测治疗反应，和治疗后监测。尽管睾丸生殖细胞肿瘤的经典血清肿瘤标志物对临床治疗至关重要，低敏感性(尤其是精原细胞瘤和畸胎瘤)和潜在的假阳性,刺激了新型生物标志物的发现和验证工作.这里,我们回顾了睾丸生殖细胞肿瘤的血清生物标志物的现状，重点关注经典的血清肿瘤标志物和新兴的microRNA标志物。
